Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer

NCT04523662 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Camrelizumab Apatinib Mesylas

Sponsor

Beijing Tsinghua Chang Gung Hospital